We describe five patients with HIV-2 infection (four antiretroviral-experienced and one antiretroviral-naive) treated with a regimen containing raltegravir. All responded to treatment as demonstrated by viral load and CD4+ T-cell count monitoring. Our series confirms the clinical effectiveness of raltegravir in HIV-2-infected patients when given with other antiretrovirals to which the virus is susceptible.
References
1.
PetersonK., JallowS., Rowland-JonesS.L., de SilvaT.I.Antiretroviral therapy for HIV-2 infection: recommendations for management in low-resource settings. AIDS Res Treat2011; 2011: 463704.
RoquebertB., DamondF., CollinG.HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother2008; 62: 914–920.
4.
GottliebG.S., SmithR.A., Dia BadianeN.M.HIV-2 integrase variation in integrase inhibitor-naive adults in Senegal, West Africa. PLoS ONE2011; 6: e22204.
5.
CharpentierC., LarrouyL., MatheronS.Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal. Antivir Ther2011; 16: 937–940.
6.
AuldA.F., TuhoM., ShiraishiR.W.Treatment outcomes of HIV-2-infected and HIV-1 and -2 dually reactive adults enrolled in Cote d'Ivoire's antiretroviral therapy program during 2004–2008.6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 17–20 July 2011, Rome, Italy. Abstract CDB 345.
7.
The African Network of Practitioners Providing care and Treatment to People living with HIV/AIDS (RESAPI, Dakar, Senegal) and the Institute of Medicine and Applied Epidemiology (IMEA, Paris, France).Diagnosis, treatment, and monitoring of HIV-2 infection and of HIV-1/HIV-2 dual infection.4th Workshop on Strategies in Antiretroviral Therapy. 13–15 May 2009, Bassam, Ivory Coast.
8.
ChiaraM., RonyZ., HomaM.Characteristics, immunological response & treatment outcomes of HIV-2 compared with HIV-1 & dual infections (HIV 1/2) in Mumbai. Indian J Med Res2010; 132: 683–689.
9.
JallowS., AlabiA., Sarge-NjieR.Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants. J Clin Microbiol2009; 47: 2200–2208.
10.
BenardA., van SighemA., TaiebA.Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group. Clin Infect Dis2011; 52: 1257–1266.
11.
GottliebG.S., EholiéS.P., NkengasongJ.N.A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa. AIDS2008; 22: 2069–2072.
12.
FrancisciD., MartinelliL., WeimerL.E.HIV-2 infection, end-stage renal disease and protease inhibitor intolerance: which salvage regimen?Clin Drug Investig2011; 31: 345–349.
13.
RoquebertB., BlumL., CollinG.Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen. AIDS2008; 22: 2045–2046.
14.
Armstrong-JamesD., StebbingJ., ScourfieldA.Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc. Antiviral Res2010; 86: 224–226.
15.
GarrettN., XuL., SmitE., FernsB., El-GadiS., AndersonJ.Raltegravir treatment response in an HIV-2 infected patient: a case report. AIDS2008; 22: 1091–1092.
16.
DamondF., LarivenS., RoquebertB.Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients. AIDS2008; 22: 665–666.
17.
CharpentierC., RoquebertB., DelelisO.Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir. Antimicrob Agents Chemother2011; 55: 1293–1295.
18.
DoroanaM., PinheiroC., OliveiraJ.Comparing treatment of HIV-1 and HIV-2 patients with raltegravir plus OBT.6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 17–20 July 2011, Rome, Italy. Abstract CDB 375.
